Genetics and genomics of radiotherapy toxicity: Towards prediction

Genome Medicine

Volumn 3, Issue 8, 2011, Pages

  West, Catharine M ^a   Barnett, Gillian C ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Genome wide association study; Radiation; Radiothe; Rapyradiogenomics; Single nucleotide polymorphism

Indexed keywords

ATM PROTEIN; CATALASE; CYTOKINE; DOUBLE STRANDED DNA; FOLLITROPIN; GLUTATHIONE TRANSFERASE; INTERLEUKIN 17; MRE11 PROTEIN; PROTEIN P53; RAD18 PROTEIN; RAD50 PROTEIN; REACTIVE OXYGEN METABOLITE; SINGLE STRANDED DNA; SMALL INTERFERING RNA; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

BLOOD VESSEL INJURY; BONE NECROSIS; BRACHYTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; COUGHING; CYTOKINE RELEASE; DENTAL CARIES; DERMATITIS; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRY SKIN; DYSKERATOSIS; DYSPHAGIA; DYSPNEA; EDEMA; EPIPHORA; ERECTILE DYSFUNCTION; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; EYE IRRITATION; FATIGUE; FUNCTIONAL GENOMICS; GASTRITIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMIC INSTABILITY; GROWTH RETARDATION; HAIR LOSS; HEARING LOSS; HUMAN; HYPOPITUITARISM; INCONTINENCE; INTENSITY MODULATED RADIATION THERAPY; KERATINIZATION; LEUKOPENIA; LYMPHEDEMA; MALABSORPTION; MUCOSA INFLAMMATION; MYELITIS; NAUSEA; NEPHRITIS; PARALYSIS; PATIENT SAFETY; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOSENSITIVITY; REPRODUCTIVE TOXICITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRANDED DNA BREAK; SKIN ATROPHY; SKIN EXFOLIATION; SKIN FIBROSIS; SKIN NECROSIS; SPINAL CORD DISEASE; STOMACH OBSTRUCTION; STOMACH ULCER; TELANGIECTASIA; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; VOMITING; XEROPHTHALMIA; XEROSTOMIA;

EID: 80053563437     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm268     Document Type: Review

References (134)

1. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76:S3-9. 10.1016/j.ijrobp.2009.09.040, 20171515.
2. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21:109-122.
3. Kerns SL, Ostrer H, Stock R, Li W, Moore J, Pearlman A, Campbell C, Shao Y, Stone N, Kusnetz L, Rosenstein BS. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78:1292-1300. 10.1016/j.ijrobp.2010.07.036, 20932654.
4. Best T, Li D, Skol AD, Kirchhoff T, Jackson SA, Yasui Y, Bhatia S, Strong LC, Domchek SM, Nathanson KL, Olopade OI, Huang RS, Mack TM, Conti DV, Offit K, Cozen W, Robison LL, Onel K. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011, 17:941-943. 10.1038/nm.2407, 21785431.
5. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005, 104:1129-1137. 10.1002/cncr.21324, 16080176.
6. Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, van den Bogaert W. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 2005, 75:355-365. 10.1016/j.radonc.2004.12.007, 16086915.
7. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 2010, 20:1235-1245. 10.1089/thy.2009.0455, 21062195.
8. Ahmed S, Winter JN, Gordon LI, Evens AM. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leuk Lymphoma 2010, 51:1163-1177. 10.3109/10428191003793366, 20470217.
9. Mayles WP. Survey of the availability and use of advanced radiotherapy technology in the UK. Clin Oncol 2010, 22:636-642. 10.1016/j.clon.2010.06.014, 20667700 .
10. Glatstein E. Intensity-modulated radiation therapy: the inverse, the converse, and the perverse. Semin Radiat Oncol 2002, 12:272-281. 10.1053/srao.2002.32433, 12118392.
11. Hong TS, Ritter MA, Tome WA, Harari PM. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer 2005, 92:1819-1824. 10.1038/sj.bjc.6602577, 2361760, 15856036.
12. Moran JM, Elshaikh MA, Lawrence TS. Radiotherapy: what can be achieved by technical improvements in dose delivery?. Lancet Oncol 2005, 6:51-58.
13. Ten Haken RK, Lawrence TS. The clinical application of intensity-modulated radiation therapy. Semin Radiat Oncol 2006, 16:224-231. 10.1016/j.semradonc.2006.04.005, 17010905.
14. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008, 9:367-375. 10.1016/S1470-2045(08)70098-6, 18374290.
15. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, Leung WK. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66:981-991. 10.1016/j.ijrobp.2006.06.013, 17145528.
16. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A'Hern RP, Sydenham MA, Emson M, Hall E, . PARSPORT trial management group Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12:127-136. 10.1016/S1470-2045(10)70290-4, 3033533, 21236730, PARSPORT trial management group.
17. Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, Burnet NG, Coles CE. Randomized controlled trial of forward-planned intensity-modulated radiotherapy for early breast cancer: interim results at 2 years. Int J Radiat Oncol Biol Phys 2011,
18. Donovan E, Bleakley N, Denholm E, Evans P, Gothard L, Hanson J, Peckitt C, Reise S, Ross G, Sharp G, Symonds-Tayler R, Tait D, Yarnold J, . Breast Technology Group Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 2007, 82:254-264. 10.1016/j.radonc.2006.12.008, 17224195, Breast Technology Group.
19. Dawson LA, Sharpe MB. Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol 2006, 7:848-858. 10.1016/S1470-2045(06)70904-4, 17012047.
20. van Herk M. Different styles of image-guided radiotherapy. Semin Radiat Oncol 2007, 17:258-267. 10.1016/j.semradonc.2007.07.003, 17903703.
21. Verellen D, De Ridder M, Linthout N, Tournel K, Soete G, Storme G. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007, 7:949-960. 10.1038/nrc2288, 18034185.
22. Ares C, Khan S, Macartain AM, Heuberger J, Goitein G, Gruber G, Lutters G, Hug EB, Bodis S, Lomax AJ. Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements?. Int J Radiat Oncol Biol Phys 2009, 76:685-697.
23. Nguyen PL, Trofimov A, Zietman AL. Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer?. Oncology 2008, 22:748-754. discussion 754, 757.
24. O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Cancer 2006, 7:45-54.
25. Martin LM, Marples B, Coffey M, Lawler M, Lynch TH, Hollywood D, Marignol L. DNA mismatch repair and the DNA damage response to ionizing radiation: making sense of apparently conflicting data. Cancer Treat Rev 2010, 36:518-527. 10.1016/j.ctrv.2010.03.008, 20413225.
26. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002, 23:687-696. 10.1093/carcin/23.5.687, 12016139.
27. Polo SE, Jackson SP. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 2011, 25:409-433. 10.1101/gad.2021311, 21363960.
28. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006, 6:702-713. 10.1038/nrc1950, 16929324.
29. Zhao W, Diz DI, Robbins ME. Oxidative damage pathways in relation to normal tissue injury. Br J Radiol 2007, 80(Spec No. 1):S23-S31.
30. Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 2011, 30:546-555. 10.1038/emboj.2010.330, 3034007, 21157431.
31. Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009, 9:351-360. 10.1038/nrc2603, 2855954, 19377507.
32. Riballo E, Critchlow SE, Teo SH, Doherty AJ, Priestley A, Broughton B, Kysela B, Beamish H, Plowman N, Arlett CF, Lehmann AR, Jackson SP, Jeggo PA. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol 1999, 9:699-702. 10.1016/S0960-9822(99)80311-X, 10395545.
33. Bentzen SM, Dorr W, Anscher MS, Denham JW, Hauer-Jensen M, Marks LB, Williams J. Normal tissue effects: reporting and analysis. Semin Radiat Oncol 2003, 13:189-202. 10.1016/S1053-4296(03)00036-5, 12903009.
34. Burnet NG, Wurm R, Nyman J, Peacock JH. Normal tissue radiosensitivity--how important is it?. Clin Oncol (R Coll Radiol) 1996, 8:25-34.
35. Bentzen SM, Overgaard M. Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. Radiother Oncol 1991, 20:159-165.
36. Bentzen SM, Overgaard M, Overgaard J. Clinical correlations between late normal tissue endpoints after radiotherapy: implications for predictive assays of radiosensitivity. Eur J Cancer 1993, 29A:1373-1376.
37. Puck TT, Marcus PI. Action of x-rays on mammalian cells. J Exp Med 1956, 103:653-666. 10.1084/jem.103.5.653, 2136626, 13319584.
38. Azria D, Ozsahin M, Kramar A, Peters S, Atencio DP, Crompton NE, Mornex F, Pelegrin A, Dubois JB, Mirimanoff RO, Rosenstein BS. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 2008, 14:6284-6288. 10.1158/1078-0432.CCR-08-0700, 2771757, 18829510.
39. Ozsahin M, Crompton NE, Gourgou S, Kramar A, Li L, Shi Y, Sozzi WJ, Zouhair A, Mirimanoff RO, Azria D. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 2005, 11:7426-7433. 10.1158/1078-0432.CCR-04-2634, 16243816.
40. Finnon P, Robertson N, Dziwura S, Raffy C, Zhang W, Ainsbury L, Kaprio J, Badie C, Bouffler S. Evidence for significant heritability of apoptotic and cell cycle responses to ionising radiation. Hum Genet 2008, 123:485-493. 10.1007/s00439-008-0500-1, 18437427.
41. Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer?. Am J Hum Genet 1999, 65:784-794. 10.1086/302544, 1377987, 10441587.
42. Surowy H, Rinckleb A, Luedeke M, Stuber M, Wecker A, Varga D, Maier C, Hoegel J, Vogel W. Heritability of baseline and induced micronucleus frequencies. Mutagenesis 2011, 26:111-117. 10.1093/mutage/geq059, 21164191.
43. Abbaszadeh F, Clingen PH, Arlett CF, Plowman PN, Bourton EC, Themis M, Makarov EM, Newbold RF, Green MH, Parris CN. A novel splice variant of the DNA-PKcs gene is associated with clinical and cellular radiosensitivity in a patient with xeroderma pigmentosum. J Med Genet 2010, 47:176-181. 10.1136/jmg.2009.068866, 19797196.
44. Little JB, Nove J. Sensitivity of human diploid fibroblast cell strains from various genetic disorders to acute and protracted radiation exposure. Radiat Res 1990, 123:87-92. 10.2307/3577662, 2371384.
45. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, Burnet NG. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009, 9:134-142. 10.1038/nrc2587, 2670578, 19148183.
46. Taylor AM, Harnden DG, Arlett CF, Harcourt SA, Lehmann AR, Stevens S, Bridges BA. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 1975, 258:427-429. 10.1038/258427a0, 1196376.
47. Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr Radiol 2009, 39(Suppl 1):S27-S31. 2656401, 19083227.
48. Tamulevicius P, Wang M, Iliakis G. Homology-directed repair is required for the development of radioresistance during S phase: interplay between double-strand break repair and checkpoint response. Radiat Res 2007, 167:1-11. 10.1667/RR0751.1, 17214519.
49. Hendry JH, West CM. Apoptosis and mitotic cell death: their relative contributions to normal-tissue and tumour radiation response. Int J Radiat Biol 1997, 71:709-719. 10.1080/095530097143716, 9246185.
50. Hoyes KP, Cai WB, Potten CS, Hendry JH. Effect of bcl-2 deficiency on the radiation response of clonogenic cells in small and large intestine, bone marrow and testis. Int J Radiat Biol 2000, 76:1435-1442. 10.1080/09553000050176199, 11098846.
51. Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, Ramsey MR, Jin J, Wong KK, Su L, Zhou D, Sharpless NE. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010, 120:2528-2536. 10.1172/JCI41402, 2898594, 20577054.
52. Kuptsova N, Chang-Claude J, Kropp S, Helmbold I, Schmezer P, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Onel K, Ambrosone CB. Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int J Cancer 2008, 122:1333-1339.
53. Aykin-Burns N, Slane BG, Liu AT, Owens KM, O'Malley MS, Smith BJ, Domann FE, Spitz DR. Sensitivity to low-dose/low-LET ionizing radiation in mammalian cells harboring mutations in succinate dehydrogenase subunit C is governed by mitochondria-derived reactive oxygen species. Radiat Res 2011, 175:150-158. 10.1667/RR2220.1, 21268708.
54. Epperly MW, Epstein CJ, Travis EL, Greenberger JS. Decreased pulmonary radiation resistance of manganese superoxide dismutase (MnSOD)-deficient mice is corrected by human manganese superoxide dismutase-Plasmid/Liposome (SOD2-PL) intratracheal gene therapy. Radiat Res 2000, 154:365-374. 10.1667/0033-7587(2000)154[0365:DPRROM]2.0.CO;2, 11023599.
55. Tan W, Huang W, Zhong Q, Schwarzenberger P. IL-17 receptor knockout mice have enhanced myelotoxicity and impaired hemopoietic recovery following gamma irradiation. J Immunol 2006, 176:6186-6193.
56. Anscher MS. Targeting the TGF-β1 pathway to prevent normal tissue injury after cancer therapy. Oncologist 2010, 15:350-359. 10.1634/theoncologist.2009-S101, 20413640.
57. Von Pfeil A, Hakenjos L, Herskind C, Dittmann K, Weller M, Rodemann HP. Irradiated homozygous TGF-β1 knockout fibroblasts show enhanced clonogenic survival as compared with TGF-β1 wild-type fibroblasts. Int J Radiat Biol 2002, 78:331-339. 10.1080/095530002753676200, 12020424.
58. Finlay M, Laperriere N, Bristow RG. Radiotherapy and Marfan syndrome: a report of two cases. Clin Oncol (R Coll Radiol) 2005, 17:54-56.
59. Andreassen CN, Alsner J, Overgaard M, Sorensen FB, Overgaard J. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM - a study based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 2006, 82:577-586. 10.1080/09553000600876637, 16966185.
60. Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol 2009, 92:299-309. 10.1016/j.radonc.2009.06.015, 19683821.
61. Teo YY. Common statistical issues in genome-wide association studies: a review on power, data quality control, genotype calling and population structure. Curr Opin Lipidol 2008, 19:133-143. 10.1097/MOL.0b013e3282f5dd77, 18388693.
62. Michikawa Y, Suga T, Ishikawa A, Hayashi H, Oka A, Inoko H, Iwakawa M, Imai T. Genome wide screen identifies microsatellite markers associated with acute adverse effects following radiotherapy in cancer patients. BMC Med Genet 2010, 11:123. 10.1186/1471-2350-11-123, 2928773, 20701746.
63. Niu N, Qin Y, Fridley BL, Hou J, Kalari KR, Zhu M, Wu TY, Jenkins GD, Batzler A, Wang L. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res 2010, 20:1482-1492. 10.1101/gr.107672.110, 2963812, 20923822.
64. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753. 10.1038/nature08494, 2831613, 19812666.
65. Morton LM, Chanock SJ. A step toward slaying the hydra of second cancers. Nat Med 2011, 17:924-925. 10.1038/nm.2428, 21818085.
66. West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, Bentzen S, Burnet N, Chang-Claude J, Chuang E, Coles C, De Ruyck K, De Ruysscher D, Dunning A, Elliott R, Fachal L, Hall J, Haustermans K, Herskind C, Hoelscher T, Imai T, Iwakawa M, Jones D, Kulich C, Langendijk JH, O'Neils P, Ozsahin M, Parliament M, Polanski A, et al. EQUAL-ESTRO Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys 2010, 76:1295-1296. 10.1016/j.ijrobp.2009.12.017, 20338472, EQUAL-ESTRO.
67. Burnet NG, Elliott RM, Dunning A, West CM. Radiosensitivity, radiogenomics and RAPPER. Clin Oncol 2006, 18:525-528.
68. Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J, Rosenstein BS. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 2006, 65:646-655. 10.1016/j.ijrobp.2006.03.006, 16751059.
69. Suga T, Ishikawa A, Kohda M, Otsuka Y, Yamada S, Yamamoto N, Shibamoto Y, Ogawa Y, Nomura K, Sho K, Omura M, Sekiguchi K, Kikuchi Y, Michikawa Y, Noda S, Sagara M, Ohashi J, Yoshinaga S, Mizoe J, Tsujii H, Iwakawa M, Imai T. Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:685-693. 10.1016/j.ijrobp.2007.06.021, 17889263.
70. West CM, Elliott RM, Burnet NG. The genomics revolution and radiotherapy. Clin Oncol (R Coll Radiol) 2007, 19:470-480.
71. Valdagni R, Rancati T, Fiorino C. Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues. Cancer 2009, 115:3141-3149. 10.1002/cncr.24356, 19544543.
72. Dehing-Oberije C, De Ruysscher D, Petit S, Van Meerbeeck J, Vandecasteele K, De Neve W, Dingemans AM, El Naqa I, Deasy J, Bradley J, Huang E, Lambin P. Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiother Oncol 2010, 97:455-461. 10.1016/j.radonc.2010.09.028, 21084125.
73. Janssens AC, van Duijn CM. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008, 17:R166-R173. 10.1093/hmg/ddn250, 18852206.
74. Guessous I, Gwinn M, Khoury MJ. Genome-wide association studies in pharmacogenomics: untapped potential for translation. Genome Med 2009, 1:46. 10.1186/gm46, 2684667, 19439031.
75. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, Freeman C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Gray E, Hunt S, Jankowski J, Langford C, et al. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2 Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011, 43:117-120. 10.1038/ng.735, 3030919, 21186350, GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2.
76. Curwen GB, Winther JF, Tawn EJ, Smart V, Whitehouse CA, Rees GS, Olsen JH, Guldberg P, Rechnitzer C, Schrøder H, Bryant PE, Sheng X, Lee HS, Chakraborty R, Boice JD. G(2) chromosomal radiosensitivity in Danish survivors of childhood and adolescent cancer and their offspring. Br J Cancer 2005, 93:1038-1045. 10.1038/sj.bjc.6602807, 2361675,2361675, 16234827.
77. Wu X, Spitz MR, Amos CI, Lin J, Shao L, Gu J, de Andrade M, Benowitz NL, Shields PG, Swan GE. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res 2006, 66:5993-5996. 10.1158/0008-5472.CAN-06-1007, 16778168.
78. Schmitz A, Bayer J, Dechamps N, Goldin L, Thomas G. Heritability of susceptibility to ionizing radiation-induced apoptosis of human lymphocyte subpopulations. Int J Radiat Oncol Biol Phys 2007, 68:1169-1177. 10.1016/j.ijrobp.2007.03.050, 1994900, 17637392.
79. Curwen GB, Cadwell KK, Winther JF, Tawn EJ, Rees GS, Olsen JH, Rechnitzer C, Schroeder H, Guldberg P, Cordell HJ, Boice JD. The heritability of G2 chromosomal radiosensitivity and its association with cancer in Danish cancer survivors and their offspring. Int J Radiat Biol 2010, 86:986-995. 10.3109/09553002.2010.496027, 20807177.
80. Jeggo P, Lavin MF. Cellular radiosensitivity: how much better do we understand it?. Int J Radiat Biol 2009, 85:1061-1081. 10.3109/09553000903261263, 19995233.
81. Matsumoto Y, Miyamoto T, Sakamoto H, Izumi H, Nakazawa Y, Ogi T, Tahara H, Oku S, Hiramoto A, Shiiki T, Fujisawa Y, Ohashi H, Sakemi Y, Matsuura S. Two unrelated patients with MRE11A mutations and Nijmegen breakage syndrome-like severe microcephaly. DNA Repair 2011, 10:314-321. 10.1016/j.dnarep.2010.12.002, 21227757.
82. O'Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA. An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. DNA Repair 2004, 3:1227-1235. 10.1016/j.dnarep.2004.03.025, 15279811.
83. Chistiakov DA, Voronova NV, Chistiakov PA. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol 2008, 47:809-824. 10.1080/02841860801885969, 18568480.
84. Waltes R, Kalb R, Gatei M, Kijas AW, Stumm M, Sobeck A, Wieland B, Varon R, Lerenthal Y, Lavin MF, Schindler D, Dörk T. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet 2009, 84:605-616. 10.1016/j.ajhg.2009.04.010, 2681000, 19409520.
85. Stewart GS, Stankovic T, Byrd PJ, Wechsler T, Miller ES, Huissoon A, Drayson MT, West SC, Elledge SJ, Taylor AM. RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling. Proc Natl Acad Sci USA 2007, 104:16910-16915. 10.1073/pnas.0708408104, 2040433, 17940005.
86. Revenkova E, Focarelli ML, Susani L, Paulis M, Bassi MT, Mannini L, Frattini A, Delia D, Krantz I, Vezzoni P, Jessberger R, Musio A. Cornelia de Lange syndrome mutations in SMC1A or SMC3 affect binding to DNA. Hum Mol Genet 2009, 18:418-427. 2722190, 18996922.
87. Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol
88. Yang M, Zhang L, Bi N, Ji W, Tan W, Zhao L, Yu D, Wu C, Wang L, Lin D. Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:1402-1407. 10.1016/j.ijrobp.2009.12.042, 20729006.
89. Langsenlehner T, Renner W, Gerger A, Hofmann G, Thurner EM, Kapp KS, Langsenlehner U. Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients. Radiother Oncol 2011, 98:387-393. 10.1016/j.radonc.2011.01.021, 21345510.
90. Mangoni M, Bisanzi S, Carozzi F, Sani C, Biti G, Livi L, Barletta E, Costantini AS, Gorini G. Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients. Int J Radiat Oncol Biol Phys
91. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PloS One 2010, 5:e12402. 10.1371/journal.pone.0012402, 2928273, 20811626.
92. Sterpone S, Cornetta T, Padua L, Mastellone V, Giammarino D, Testa A, Tirindelli D, Cozzi R, Donato V. DNA repair capacity and acute radiotherapy adverse effects in Italian breast cancer patients. Mutat Res 2010, 684:43-48.
93. Alsbeih G, Al-Harbi N, Al-Hadyan K, El-Sebaie M, Al-Rajhi N. Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat Res 2010, 173:505-511. 10.1667/RR1769.1, 20334523.
94. Zhou L, Xia J, Li H, Dai J, Hu Y. Association of XRCC1 variants with acute skin reaction after radiotherapy in breast cancer patients. Cancer Biother Radiopharm 2010, 25:681-685. 10.1089/cbr.2010.0811, 21204762.
95. Zhang L, Yang M, Bi N, Ji W, Wu C, Tan W, Zhao L, Yu D, Lin D, Wang L. Association of TGF-β1 and XPD polymorphisms with severe acute radiation-induced esophageal toxicity in locally advanced lung cancer patients treated with radiotherapy. Radiother Oncol 2010, 97:19-25. 10.1016/j.radonc.2010.08.015, 20832885.
96. Zschenker O, Raabe A, Boeckelmann IK, Borstelmann S, Szymczak S, Wellek S, Rades D, Hoeller U, Ziegler A, Dikomey E, Borgmann K. Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity. Radiother Oncol 2010, 97:26-32. 10.1016/j.radonc.2010.01.016, 20170971.
97. Ishikawa A, Suga T, Shoji Y, Kato S, Ohno T, Ishikawa H, Yoshinaga S, Ohara K, Ariga H, Nomura K, Shibamoto Y, Ishikawa KI, Moritake T, Michikawa Y, Iwakawa M, Imai T. Genetic variants of NPAT-ATM and AURKA are associated with an early adverse reaction in the gastrointestinal tract of patients with cervical cancer treated with pelvic radiation therapy. Int J Radiat Oncol Biol Phys
98. Martin S, Sydenham M, Haviland J, A'Hern R, Owen R, Bliss J, Yarnold J. Test of association between variant tgbeta1 alleles and late adverse effects of breast radiotherapy. Radiother Oncol 2010, 97:15-18. 10.1016/j.radonc.2010.03.019, 20435363.
99. Barnett GC, Coles CE, Burnet NG, Pharoah PD, Wilkinson J, West CM, Elliott RM, Baynes C, Dunning AM. No association between SNPs regulating TGF-beta1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother Oncol 2010, 97:9-14. 10.1016/j.radonc.2009.12.006, 3120654, 20096948.
100. Fogarty GB, Muddle R, Sprung CN, Chen W, Duffy D, Sturm RA, McKay MJ. Unexpectedly severe acute radiotherapy side effects are associated with single nucleotide polymorphisms of the melanocortin-1 receptor. Int J Radiat Oncol Biol Phys 2010, 77:1486-1492. 10.1016/j.ijrobp.2009.07.1690, 19932942.
101. Chang-Claude J, Ambrosone CB, Lilla C, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Popanda O. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 2009, 100:1680-1686. 10.1038/sj.bjc.6605036, 2696768, 19367277.
102. Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, Milas L, Wei Q. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009, 27:3370-3378. 10.1200/JCO.2008.20.6763, 19380441.
103. Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, Boterberg T, Willems P, Vral A, De Neve W, Thierens H. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys 2009, 73:1187-1195. 10.1016/j.ijrobp.2008.08.073, 19251090.
104. Popanda O, Marquardt JU, Chang-Claude J, Schmezer P. Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res 2009, 667:58-69.
105. Meyer A, Dörk T, Bogdanova N, Brinkhaus MJ, Wiese B, Hagemann J, Serth J, Bremer M, Baumann R, Karstens JH, Machtens S. TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy. World J Urol 2009, 27:371-377. 10.1007/s00345-008-0354-0, 19039592.
106. Langsenlehner T, Kapp KS, Langsenlehner U. TGFB1 single-nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. In regard to Peters et al. (Int J Radiat Oncol Biol Phys 2008;70:752-759). Int J Radiat Oncol Biol Phys 2008, 71:960. author reply 960-961.
107. Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri RJ, Stone NN, Ostrer H, Rosenstein BS. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:752-759. 10.1016/j.ijrobp.2007.05.023, 17689884.
108. Isomura M, Oya N, Tachiiri S, Kaneyasu Y, Nishimura Y, Akimoto T, Hareyama M, Sugita T, Mitsuhashi N, Yamashita T, Aoki M, Sai H, Hirokawa Y, Sakata K, Karasawa K, Tomida A, Tsuruo T, Miki Y, Noda T, Hiraoka M. IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res 2008, 14:6683-6689. 10.1158/1078-0432.CCR-07-4389, 18927311.
109. Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 2008, 170:49-59. 10.1667/RR1219.1, 18582155.
110. Badie C, Dziwura S, Raffy C, Tsigani T, Alsbeih G, Moody J, Finnon P, Levine E, Scott D, Bouffler S. Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment. Br J Cancer 2008, 98:1845-1851. 10.1038/sj.bjc.6604381, 2410125, 18493234.
111. Suga T, Iwakawa M, Tsuji H, Ishikawa H, Oda E, Noda S, Otsuka Y, Ishikawa A, Ishikawa K, Shimazaki J, Mizoe JE, Tsujii H, Imai T. Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:808-813. 10.1016/j.ijrobp.2008.01.029, 18374504.
112. Giotopoulos G, Symonds RP, Foweraker K, Griffin M, Peat I, Osman A, Plumb M. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer 2007, 96:1001-1007. 10.1038/sj.bjc.6603637, 2360097, 17325707.
113. Edvardsen H, Tefre T, Jansen L, Vu P, Haffty BG, Fossa SD, Kristensen VN, Borresen-Dale AL. Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence. Radiat Oncol 2007, 2:25. 10.1186/1748-717X-2-25, 1971057, 17623063.
114. Edvardsen H, Kristensen VN, Grenaker Alnaes GI, Bohn M, Erikstein B, Helland A, Borresen-Dale AL, Fossa SD. Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67:1163-1171. 10.1016/j.ijrobp.2006.11.009, 17336217.
115. Ahn J, Ambrosone CB, Kanetsky PA, Tian C, Lehman TA, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Chang-Claude J. Polymorphisms in genes related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer. Clin Cancer Res 2006, 12:7063-7070. 10.1158/1078-0432.CCR-06-0039, 17145829.
116. Brem R, Cox DG, Chapot B, Moullan N, Romestaing P, Gerard JP, Pisani P, Hall J. The XRCC1 -77T->C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 2006, 27:2469-2474. 10.1093/carcin/bgl114, 16829685.
117. Tan XL, Popanda O, Ambrosone CB, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 2006, 97:255-262. 10.1007/s10549-005-9119-2, 16331344.
118. Popanda O, Tan XL, Ambrosone CB, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J. Genetic polymorphisms in the DNA double-strand break repair genes XRCC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2006, 15:1048-1050. 10.1158/1055-9965.EPI-06-0046, 16702393.
119. De Ruyck K, Van Eijkeren M, Claes K, Bacher K, Vral A, De Neve W, Thierens H. TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 2006, 65:1240-1248. 10.1016/j.ijrobp.2006.03.047, 16798416.
120. Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G, Field C, Greiner R, Hanson J, Cass CE, Parliament M. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006, 12:2545-2554. 10.1158/1078-0432.CCR-05-2703, 16638864.
121. Ambrosone CB, Tian C, Ahn J, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Chang-Claude J. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res 2006, 8:R40. 10.1186/bcr1526, 1779469, 16848913.
122. Kornguth DG, Garden AS, Zheng Y, Dahlstrom KR, Wei Q, Sturgis EM. Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. Int J Radiat Oncol Biol Phys 2005, 62:665-671. 10.1016/j.ijrobp.2004.11.026, 15936543.
123. Chang-Claude J, Popanda O, Tan XL, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Ambrosone CB. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005, 11:4802-4809. 10.1158/1078-0432.CCR-04-2657, 16000577.
124. Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J, Owen R, Homewood J, Bliss J, Yarnold J. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 2005, 75:18-21. 10.1016/j.radonc.2004.12.012, 15878096.
125. De Ruyck K, Wilding CS, Van Eijkeren M, Morthier R, Tawn EJ, Thierens H. Microsatellite polymorphisms in DNA repair genes XRCC1, XRCC3 and XRCC5 in patients with gynecological tumors: association with late clinical radiosensitivity and cancer incidence. Radiat Res 2005, 164:237-244. 10.1667/RR3417.1, 16137195.
126. Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall J. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003, 12:1168-1174.
127. Quarmby S, Fakhoury H, Levine E, Barber J, Wylie J, Hajeer AH, West C, Stewart A, Magee B, Kumar S. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 2003, 79:137-143.
128. Andreassen CN, Alsner J, Overgaard M, Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003, 69:127-135. 10.1016/j.radonc.2003.09.010, 14643949.
129. Angèle S, Romestaing P, Moullan N, Vuillaume M, Chapot B, Friesen M, Jongmans W, Cox DG, Pisani P, Gérard JP, Hall J. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 2003, 63:8717-8725.
130. Green H, Ross G, Peacock J, Owen R, Yarnold J, Houlston R. Variation in the manganese superoxide dismutase gene (SOD2) is not a major cause of radiotherapy complications in breast cancer patients. Radiother Oncol 2002, 63:213-216. 10.1016/S0167-8140(02)00079-8, 12063011.
131. Severin DM, Leong T, Cassidy B, Elsaleh H, Peters L, Venter D, Southey M, McKay M. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys 2001, 50:1323-1331. 10.1016/S0360-3016(01)01608-X, 11483345.
132. Bhatti S, Kozlov S, Farooqi AA, Naqi A, Lavin M, Khanna KK. ATM protein kinase: the linchpin of cellular defenses to stress. Cell Mol Life Sci
133. Malaise EP, Fertil B, Deschavanne PJ, Chavaudra N, Brock WA. Initial slope of radiation survival curves is characteristic of the origin of primary and established cultures of human tumor cells and fibroblasts. Radiat Res 1987, 111:319-333. 10.2307/3576988, 3628719.
134. West CM, Davidson SE, Elyan SA, Valentine H, Roberts SA, Swindell R, Hunter RD. Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2001, 51:10-15.